title: Clinical presentation of Von Hippel Lindau syndrome type 2B associated with VHL p.A149S mutation in a large Turkish family.
abstract: Von Hippel Lindau (VHL) syndrome is an autosomal dominant disorder characterized by benign and malignant tumors. This study presents the clinical and genetic features of VHL syndrome in a Turkish family. For the diagnosis of pheochromocytoma-related diseases, 49 family members from three generations were evaluated between March 2008 and January 2013. Family members were examined to identify components of pheochromocytoma-related genetic syndromes through physical examination, laboratory tests, and imaging methods. For the causative mutation, sequence analysis of VHL gene was performed. Nine patients were diagnosed with pheochromocytoma. Lumbal spinal hemangioblastoma and pancreatic neuroendocrine tumor without pheochromocytoma were detected in one patient. In patients with pheochromocytoma, additional tumors, such as retinal angioma, renal cell carcinoma, pancreatic serous cystadenoma, and pancreatic neuroendocrine tumors were detected. All patients were diagnosed as VHL syndrome type 2B. Sequence analysis of VHL gene revealed heterozygous p.A149S mutation in all symptomatic patients and in seven of the asymptomatic family members. This is the first study that identified VHL p.A149S mutation in a Turkish family with VHL syndrome. However, VHL p.A149S mutation was identified in an American family by Atuk et al. (J Clin Endocrinol Metab, 83:117-120, 14) and the family was defined as VHL type 2A. In our study, the family was identified as VHL type 2B. This variability in the phenotypic features suggests that further studies are required to beter assess the genotype-phenotype correlation in such cases.
authors.affiliation: Department of Endocrinology and Metabolism, Ministry of Health, Ankara Numune Training and Research Hospital, 06622, Sıhhiye, Ankara, Turkey, turkanmete@yahoo.com.
authors.forename: T
authors.initials: T
authors.lastname: Mete
authors.forename: D
authors.initials: D
authors.lastname: Berker
authors.forename: E
authors.initials: E
authors.lastname: Yilmaz
authors.forename: G
authors.initials: G
authors.lastname: Ozgen
authors.forename: Y
authors.initials: Y
authors.lastname: Yalcin
authors.forename: M
authors.initials: M
authors.lastname: Tuna
authors.forename: D
authors.initials: D
authors.lastname: Ciliz
authors.forename: M
authors.initials: M
authors.lastname: Onen
authors.forename: Y
authors.initials: Y
authors.lastname: Aydin
authors.forename: S
authors.initials: S
authors.lastname: Guler
mesh_terms: D000293:Adolescent; D000328:Adult; D000409:Alanine / Q000235:genetics; D019943:Amino Acid Substitution; D005190:Family; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D010375:Pedigree; D012694:Serine / Q000235:genetics; D014421:Turkey; D051794:Von Hippel-Lindau Tumor Suppressor Protein / Q000235:genetics*; D055815:Young Adult; D006623:von Hippel-Lindau Disease / Q000235:genetics*
chemical_list: D012694:Serine; D051794:Von Hippel-Lindau Tumor Suppressor Protein; C497446:VHL protein, human; D000409:Alanine